Universität zu Köln

Health Literacy in Patients Wearing Prosthetic Eyes: A Prospective Cross-Sectional Study (2022) Rokohl AC, Pine NS, Adler W, Bartenschlager LAK, Matos PAW, Trester M, Pine KR, et al. Journal article Seizure Semiology in Antibody-Associated Autoimmune Encephalitis (2022) Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, et al. Journal article Epidemiology of inherited epidermolysis bullosa in Germany (2022) Has C, Hess M, Anemueller W, Blume-Peytavi U, Emmert S, Foelster-Holst R, Frank J, et al. Journal article Prevalence of sport injuries in Olympic combat sports: a cross-sectional study examining one Olympic period (2022) Lambert C, Ritzmann R, Lambert S, Lachmann D, Malliaropoulos NG, Gesslein M, Peters N, Shafizadeh S Journal article Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 (2022) Vogel E, Kocher K, Priller A, Cheng CC, Steininger P, Liao BH, Körber N, et al. Journal article Novel Heritable Human COSMC Mutation Results in a Multisystemic Chaperonopathy (2022) Aryal RP, Erger F, Reusch B, Matsumoto Y, Meyer R, Zeng J, Knopp C, et al. Conference contribution The genomic landscape across 474 surgically accessible epileptogenic human brain lesions (2022) A López-Rivera J, Leu C, Macnee M, Khoury J, Hoffmann L, Coras R, Kobow K, et al. Journal article, Original article Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors (2022) Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Braegelmann J, Lohneis P, et al. Journal article MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT) (2022) Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, et al. Journal article Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus (2022) Hoppe S, Meder L, Gebauer F, Ullrich RT, Zander T, Hillmer AM, Buettner R, et al. Journal article